Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Reza Parwaresch(Klinikum Braunschweig), E.D. Kreuser, E Terhardt-Kasten, Markus Tiemann(European Central Bank), Martin Busch, Andreas Neubauer(RWTH Aachen University), Gerhard Helm, H.-H. Wöltjen, Ulrich Kaiser(University of Applied Sciences Landshut), Richard Herrmann(Heidelberg University), Halard Stein, Michael Unterhalt, M. Freund, H. Middeke, Lorenz Trümper(University of Göttingen), R Hanrath
Cited by 113
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Diagnostic criteria and classification of mastocytosis: a consensus proposal
|Leukemia Research|2001|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k